Latest News
ImmuPharma selects Kymos Group as bioanalytical partner for Kapiglucagon
10 August 2026 - Specialist drug discovery and development company ImmuPharma plc (LSE AIM: IMM) announced on Monday that it has selected Kymos Germany/Prolytic, part of Kymos Group, as its bioanalytical contract research organisation partner for the...
Neurocrine Biosciences initiates Phase 1 study of GLP-1/GIP/glucagon receptor triple agonist
10 August 2026 - US biopharmaceutical company Neurocrine Biosciences Inc (Nasdaq:NBIX) announced on Friday the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'1968, an investigational GLP-1/G...
Akeso Advances reports first patient dosed in AK146D1 combined with ivonescimab breast cancer study
10 August 2026 - Chinese biopharmaceutical company Akeso Inc (HK:9926) announced on Monday that the first patient has been dosed in a Phase II clinical study evaluating AK146D1, its internally developed TROP2/Nectin-4 bispecific antibody-drug conjuga...
Alebund's AP301 NDA accepted for review by China's NMPA
7 August 2026 - Renal-focused biopharmaceutical company Alebund Pharmaceuticals (Jiangsu) Limited (HKEX:09637) announced on Friday that China's National Medical Products Administration (NMPA) has accepted for review its New Drug Application (NDA...
BioInvent receives FDA Fast Track designation for BI-1808 in ovarian cancer
7 August 2026 - Swedish biotech company BioInvent International AB (STO:BINV) announced on Friday that the US Food and Drug Administration (FDA) has granted Fast Track designation to its first-in-class anti-TNFR2 antibody BI-1808, in combination with...